Macrogenics opened lower at $2.31, compared with its previous close of $2.32. In the last trading session, the stock traded between $2.24 and $2.43. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Macrogenics is now worth
$ 11.46
Resulting in a loss of
$ 88.54 (88.54%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.02 (-0.99%)
Day High
$2.43
Day Low
$2.24
Day Open
$2.31
Prev Close
$2.32
Volume
8,14,279
1W Return
-0.78%
1M Return
-38.34%
3M Return
-41.48%
6M Return
-22.14%
1Y Return
51.12%
Market Cap ($ Mn)
146
PE Ratio
-
PB Ratio
6.14
PEG Ratio
-
ROE
-102.39%
ROCE
-35.65%
EPS (TTM)
$0.31
1 Week
-0.78%
1 Month
-38.34%
3 Months
-41.48%
6 Months
-22.14%
9 Months
33.55%
Macrogenics Q3 Results: Loss widens to $0.34 per share, sales down 74%
Macrogenics posted a quarterly loss of $(0.34) per share, missing the $0.03 consensus estimate. Sales declined 74.37% YoY to $18.667 million, well below the $46.403 million forecast. The result contrasts sharply with the $0.27 earnings per share reported in the same quarter last year. Revenue missed analyst expectations by nearly 60%, indicating a significant top-line shortfall.
TodayMacroGenics doses first patient in Phase 1 study of MGC030
MacroGenics dosed the first patient in Phase 1 study of MGC030. MGC030 is the company's third ADC in active clinical development. Study targets advanced solid tumors including urothelial and colorectal cancers. Dose escalation phase enrolls up to 54 participants initially.
28 days agoMacroGenics CEO to present at H.C. Wainwright conference on Sept 16
Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation is scheduled for September 16, 2026, at 9:30 am ET. A live webcast will be available on the company’s Investor Relations website. An archived replay will be accessible for 30 days post-event. MacroGenics focuses on developing monoclonal antibody-based therapeutics for cancer treatment.
2mo agoMacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss
MacroGenics reported Q2 2026 adjusted EPS of $(0.27), missing the $(0.13) estimate by 107.69%. Revenue of $32.832 million missed the $67.456 million forecast by 51.33%, though it rose 47.62% YoY. Net income turned positive to $19.5 million due to an $89.2 million gain from discontinued operations.
3mo agoMacroGenics earns $10M as Gilead licenses bispecific program
MacroGenics, Inc. secured a $10 million payment following Gilead Sciences' exercise of an option to exclusively license a preclinical bispecific program under their 2022 collaboration. The licensed asset uses MacroGenics' TRIDENT platform for solid tumors. MacroGenics remains eligible for up to $1.6 billion in additional milestone payments and royalties.
3mo agoMacroGenics sells GMP ops to Bora for $122.5 million
MacroGenics has sold its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million, effective July 02, 2026. The deal includes the transfer of sites in Rockville and Frederick, Maryland, and approximately 140 employees. A supply agreement ensures Bora will continue supporting MacroGenics' pipeline needs.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Macrogenics is now worth
$ 11.46
Resulting in a loss of
$ 88.54 (88.54%)
Note: Past profits do not guarantee future returns.
